Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1878

10.17650/1726-9776-2024-20-3-168-171

RESOLUTION

РЕЗОЛЮЦИЯ

Resolution of the Expert Council on the topic “Avelumab + axitinib in the 1st line therapy of patients with metastatic renal cell carcinoma. Overall survival in the JAVELIN Renal 101 trial”

Резолюция по итогам Совета экспертов на тему «Авелумаб + акситиниб в 1-й линии терапии пациентов с метастатическим почечно-клеточным раком. Результаты общей выживаемости в исследовании JAVELIN Renal 101»

24112024

203

1681712411202424112024

https://oncourology.abvpress.ru/oncur/article/view/1878

1. Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI: 10.1056/NEJMoa1816047

Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI: 10.1056/NEJMoa1816047

2. Motzer R.J., Penkov K., Uemura H. et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol 2024;42(suppl 16):4508. DOI: 10.1200/JCO.2024.42.16_suppl.4508

Motzer R.J., Penkov K., Uemura H. et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol 2024;42(suppl 16):4508. DOI: 10.1200/JCO.2024.42.16_suppl.4508

3. Haanen J.B.A.G., Larkin J., Choueiri T.K. et al. Extended followup from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 2023;8(3):101210. DOI: 10.1016/j.esmoop.2023.101210

Haanen J.B.A.G., Larkin J., Choueiri T.K. et al. Extended followup from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 2023;8(3):101210. DOI: 10.1016/j.esmoop.2023.101210

4. Shen M., Chen G., Xie Q. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int 2020;104(7-8):533–41. DOI: 10.1159/000506296

Shen M., Chen G., Xie Q. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int 2020;104(7-8):533–41. DOI: 10.1159/000506296

5. Wang Z., Peng S., Xie H. et al. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a metaanalysis based on 1863 individuals. Clin Exp Med 2018;18:165–75. DOI: 10.1007/s10238-018-0488-3

Wang Z., Peng S., Xie H. et al. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a metaanalysis based on 1863 individuals. Clin Exp Med 2018;18:165–75. DOI: 10.1007/s10238-018-0488-3

6. Iacovelli R., Nolè F., Verri E. et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and metaanalysis. Target Oncol 2016;11(2):143–8. DOI: 10.1007/s11523-015-0392-7

Iacovelli R., Nolè F., Verri E. et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and metaanalysis. Target Oncol 2016;11(2):143–8. DOI: 10.1007/s11523-015-0392-7

7. Möller K., Fraune C., Blessin N.C. et al. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. Int Urol Nephrol 2021;53(12):2493–503. DOI: 10.1007/s11255-021-02841-7

Möller K., Fraune C., Blessin N.C. et al. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. Int Urol Nephrol 2021;53(12):2493–503. DOI: 10.1007/s11255-021-02841-7

8. Carretero-González A., Lora D., Martín Sobrino I. et al. The Value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 2020;12(7):1945. DOI: 10.3390/cancers12071945

Carretero-González A., Lora D., Martín Sobrino I. et al. The Value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 2020;12(7):1945. DOI: 10.3390/cancers12071945

9. Motzer R.J., Robbins P.B., Powles T. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 2020;26(11):1733–41. DOI: 10.1038/s41591-020-1044-8

Motzer R.J., Robbins P.B., Powles T. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med 2020;26(11):1733–41. DOI: 10.1038/s41591-020-1044-8

10.

10. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma. J Clin Oncol 2023;41(suppl_17):LBA4501. DOI: 10.1200/JCO.2023.41.17_suppl.LBA4501

Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma. J Clin Oncol 2023;41(suppl_17):LBA4501. DOI: 10.1200/JCO.2023.41.17_suppl.LBA4501

11.

11. Bourlon M.T., Escudier B., Burotto M. et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial. J Clin Oncol 2024;42(4):362. DOI: 10.1200/JCO.2024.42.4_suppl.362

Bourlon M.T., Escudier B., Burotto M. et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial. J Clin Oncol 2024;42(4):362. DOI: 10.1200/JCO.2024.42.4_suppl.362

12.

12. Motzer R.J., Porta C., Eto M. et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42(11):1222–8. DOI: 10.1200/JCO.23.01569

Motzer R.J., Porta C., Eto M. et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42(11):1222–8. DOI: 10.1200/JCO.23.01569

13.

13. Рак паренхимы почки. Клинические рекомендации Минздрава России. Доступно по: https://cr.minzdrav.gov.ru/schema/10_3

Рак паренхимы почки. Клинические рекомендации Минздрава России. Доступно по: https://cr.minzdrav.gov.ru/schema/10_3

14.

14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Kidney cancer. Version 1.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed July 16, 2024).

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Kidney cancer. Version 1.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed July 16, 2024).

15.

15. Bæk Møller N., Budolfsen C., Grimm D. et al. Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci 2019;20(19):4712. DOI: 10.3390/ijms20194712

Bæk Møller N., Budolfsen C., Grimm D. et al. Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci 2019;20(19):4712. DOI: 10.3390/ijms20194712

16.

16. Rini B.I., Atkins M.B., Choueiri T.K. Time to resolution of axitinibrelated adverse events after treatment interruption in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2021;19(5):e306–12. DOI: 10.1016/j.clgc.2021.03.019

Rini B.I., Atkins M.B., Choueiri T.K. Time to resolution of axitinibrelated adverse events after treatment interruption in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2021;19(5):e306–12. DOI: 10.1016/j.clgc.2021.03.019

17.

17. Инструкция по медицинскому применению препарата Инлита (акситиниб). Регистрационный номер: РУ ЛП-№(001121)-(РГ-RU).

Инструкция по медицинскому применению препарата Инлита (акситиниб). Регистрационный номер: РУ ЛП-№(001121)-(РГ-RU).